Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix, Shukui Qin, Philippe Merle, Alessandro Granito, Yi‐Hsiang Huang, G. Bodoky, Marc Pracht, Osamu Yokosuka, Olivier Rosmorduc, В. В. Бредер, René Gérolami, Gianluca Masi, Paul J. Ross, Tianqiang Song, Jean-Pierre Bronowicki, Isabelle Ollivier‐Hourmand, Masatoshi Kudo, Ann‐Lii Cheng, Josep M. Llovet, Richard S. Finn, Marie-Aude LeBerre, Annette Baumhauer, Gerold Meinhardt, Guohong Han (2016). Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 389(10064), pp. 56-66, DOI: 10.1016/s0140-6736(16)32453-9.
Article355 days agoReal-world dosing of regorafenib in patients with unresectable hepatocellular carcinoma (uHCC): Final analysis of the prospective, observational REFINE study.
Richard S. Finn, Philippe Merle, Masafumi Ikeda, Heinz‐Josef Klümpen, Gianluca Masi, Alessandro Granito, Ho Yeong Lim, Masatoshi Kudo, Shukui Qin, René Gerolami, Yi‐Hsiang Huang, Do Young Kim, Matthias Pinter, Naoya Kato, Masayuki Kurosaki, Kazushi Numata, Javeed Khan, Kirhan Özgürdal, Yoon Jun Kim (2023). Real-world dosing of regorafenib in patients with unresectable hepatocellular carcinoma (uHCC): Final analysis of the prospective, observational REFINE study.. , 41(4_suppl), DOI: https://doi.org/10.1200/jco.2023.41.4_suppl.518.
Article17 days agoOverall Survival (OS) Update: 2-year follow-up from the phase-3 RESORCE trial of Regorafenib for patients with hepatocellular carcinoma (HCC) progressing on Sorafenib
D. Waldschmidt, Alessandro Granito, Philippe Merle, Yi‐Hsiang Huang, G. Bodoky, Osamu Yokosuka, Olivier Rosmorduc, Валерий Владимирович Бредер, René Gerolami, Gianluca Masi, P.J. Ross, Susan Quinn, Tianqiang Song, JP Bronowicki, Isabelle Olivier-Hourmand, Masatoshi Kudo, MA LeBerre, Annette Baumhauer, Gudrun Meinhardt, Guorong Han, Jordi Bruix (2019). Overall Survival (OS) Update: 2-year follow-up from the phase-3 RESORCE trial of Regorafenib for patients with hepatocellular carcinoma (HCC) progressing on Sorafenib. , DOI: https://doi.org/10.1055/s-0039-1695314.
Article17 days ago4:12 PM Abstract No. 379 Updated overall survival (OS) analysis from the international, phase 3, randomized, placebo-controlled RESORCE trial of regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment
Guohong Han, Philippe Merle, Alessandro Granito, Yi‐Hsiang Huang, G. Bodoky, Osamu Yokosuka, Olivier Rosmorduc, В. В. Бредер, René Gerolami, Gianluca Masi, Paul J. Ross, Shukui Qin, Tianqiang Song, Jean‐Pierre Bronowicki, Isabelle Ollivier‐Hourmand, Masatoshi Kudo, Marie-Aude LeBerre, Annette Baumhauer, Gerold Meinhardt, Jordi Bruix (2018). 4:12 PM Abstract No. 379 Updated overall survival (OS) analysis from the international, phase 3, randomized, placebo-controlled RESORCE trial of regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment. , 29(4), DOI: https://doi.org/10.1016/j.jvir.2018.01.420.
Article17 days agoTime course of treatment-emergent adverse events (TEAEs) in the randomized, controlled phase 3 RESORCE trial of regorafenib for patients with hepatocellular carcinoma progressing on sorafenib treatment.
Philippe Merle, Alessandro Granito, Yi‐Hsiang Huang, G. Bodoky, Marc Pracht, Osamu Yokosuka, Olivier Rosmorduc, Breder , René Gerolami, Gianluca Masi, P.J. Ross, Shukui Qin, Tiebing Song, JP Bronowicki, Isabelle Ollivier‐Hourmand, Masatoshi Kudo, Sarah Schlief, Sabine Fiala-Buskies, Gudrun Meinhardt, Jordi Bruix (2017). Time course of treatment-emergent adverse events (TEAEs) in the randomized, controlled phase 3 RESORCE trial of regorafenib for patients with hepatocellular carcinoma progressing on sorafenib treatment.. , 66
Article17 days ago